Zhang Chuang, Huang Zhanpeng, Huang Xinyue, Ma Yanni, Cao Yifan, Zhang Zhixiong, Wang Rui, Ren Haigang, Zheng Longtai, Liu Chun-Feng, Wang Guanghui
Laboratory of Molecular Neuropathology, Department of Pharmacology, Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu, China.
Department of Pharmacy, The Affiliated Zhangjiagang Hospital of Soochow University, Suzhou, Jiangsu, China.
Autophagy. 2025 Aug;21(8):1623-1643. doi: 10.1080/15548627.2024.2448914. Epub 2025 Jan 14.
The aggregation and transmission of SNCA/α-synuclein (synuclein, alpha) is a hallmark pathology of Parkinson disease (PD). PLK2 (polo like kinase 2) is an evolutionarily conserved serine/threonine kinase that is more abundant in the brains of all family members, is highly expressed in PD, and is linked to SNCA deposition. However, in addition to its role in phosphorylating SNCA, the role of PLK2 in PD and the mechanisms involved in triggering neurodegeneration remain unclear. Here, we found that PLK2 regulated SNCA pathology independently of S129. Overexpression of PLK2 promoted SNCA preformed fibril (PFF)-induced aggregation of wild-type SNCA and mutant SNCA. Genetic or pharmacological inhibition of PLK2 attenuated SNCA deposition and neurotoxicity. Mechanistically, PLK2 exacerbated the propagation of SNCA pathology by impeding the clearance of SNCA aggregates by blocking macroautophagic/autophagic flux. We further showed that PLK2 phosphorylated S1098 of DCTN1 (dynactin 1), a protein that controls the movement of organelles, leading to impaired autophagosome-lysosome fusion. Furthermore, genetic suppression of PLK2 alleviated SNCA aggregation and motor dysfunction . Our findings suggest that PLK2 negatively regulates autophagy, promoting SNCA pathology, suggesting a role for PLK2 in PD.: AD: Alzheimer disease; AMPK: AMP-activated protein kinase; CASP3: caspase 3; DCTN1: dynactin 1; LBs: lewy bodies; LDH: lactate dehydrogenase; LAMP1: lysosomal associated membrane protein 1; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MAP2: microtubule associated protein 2; MTOR: mechanistic target of rapamycin kinase; NH4Cl: ammonium chloride; p-SNCA: phosphorylation of SNCA at S129; PD: Parkinson disease; PFF: preformed fibril; PI: propidium iodide; PLK2: polo like kinase 2; PRKAA/AMPK: protein kinase AMP-activated catalytic subunit alpha; shRNA: short hairpin RNA; SNCA: synuclein, alpha; SQSTM1/p62: sequestosome 1; TH: tyrosine hydroxylase; TX: Triton X-100; ULK1: unc-51 like autophagy activating kinase 1.
突触核蛋白α(SNCA/α-synuclein)的聚集与传播是帕金森病(PD)的标志性病理特征。PLK2(polo样激酶2)是一种进化上保守的丝氨酸/苏氨酸激酶,在所有家庭成员的大脑中含量更高,在帕金森病中高表达,且与SNCA沉积有关。然而,除了其在磷酸化SNCA中的作用外,PLK2在帕金森病中的作用以及引发神经退行性变的机制仍不清楚。在此,我们发现PLK2独立于S129调节SNCA病理。PLK2的过表达促进了野生型SNCA和突变型SNCA的由预形成纤维(PFF)诱导的聚集。PLK2的基因或药理学抑制减弱了SNCA沉积和神经毒性。从机制上讲,PLK2通过阻断巨自噬/自噬通量来阻碍SNCA聚集体的清除,从而加剧了SNCA病理的传播。我们进一步表明,PLK2使动力蛋白1(DCTN1)的S1098位点磷酸化,DCTN1是一种控制细胞器运动的蛋白质,导致自噬体-溶酶体融合受损。此外,PLK2的基因抑制减轻了SNCA聚集和运动功能障碍。我们的研究结果表明,PLK2负向调节自噬,促进SNCA病理,提示PLK2在帕金森病中的作用。:AD:阿尔茨海默病;AMPK:AMP激活的蛋白激酶;CASP3:半胱天冬酶3;DCTN1:动力蛋白1;LBs:路易小体;LDH:乳酸脱氢酶;LAMP1:溶酶体相关膜蛋白1;MAP1LC3/LC3:微管相关蛋白1轻链3;MAP2:微管相关蛋白2;MTOR:雷帕霉素激酶的机制性靶点;NH4Cl:氯化铵;p-SNCA:SNCA在S129位点的磷酸化;PD:帕金森病;PFF:预形成纤维;PI:碘化丙啶;PLK2:polo样激酶2;PRKAA/AMPK:蛋白激酶AMP激活的催化亚基α;shRNA:短发夹RNA;SNCA:突触核蛋白α;SQSTM1/p62:聚集体蛋白1;TH:酪氨酸羟化酶;TX:曲拉通X-100;ULK1:unc-51样自噬激活激酶1